Open Access

Silencing TAK1 alters gene expression signatures in bladder cancer cells

  • Authors:
    • Jimin Chen
    • Nan Zhang
    • Jiaming Wen
    • Zhewei Zhang
  • View Affiliations

  • Published online on: March 7, 2017     https://doi.org/10.3892/ol.2017.5819
  • Pages: 2975-2981
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to identify the differentially expressed genes (DEGs) that are induced by the silencing of transforming growth factor‑β‑activated kinase 1 (TAK1) in bladder cancer cells and to analyze the potential biological effects. Dataset GSE52452 from mutant fibroblast growth factor receptor 3 (FGFR3) bladder cancer cells transfected with control siRNA or TAK1-specific siRNA was downloaded from Gene Expression Omnibus. The DEGs between the two groups were identified using Limma package following data pre‑processing by Affy in Bioconductor. Enrichment analysis of DEGs was performed using the Database for Annotation, Visualization and Integrated Discovery, followed by functional annotation using TRANSFAC, TSGene and TAG databases. Integrated networks were constructed by Cytoscape and sub‑networks were extracted employing BioNet, followed by enrichment analysis of DEGs in the sub‑network. A total of 43 downregulated and 21 upregulated genes were obtained. The downregulated genes were enriched in five pathways, including NOD‑like receptor signaling pathway and functions related to cellular response. The upregulated genes were associated with cellular developmental processes. Transcription factor EGR1 and 9 tumor‑associated genes were screened from the DEGs. Among the DEGs, 10 hub nodes may represent important roles in the complex metabolic network, including EGFR, CYP3A5, MAP3K7, GSTA1, PTHLH, ALDH1A1, KCND2, EGR1, ARRB1 and ITPR1. Additionally, EGFR was correlated with ERBB2, GRB2 and PIK3R1, and these were enriched in ErbB signaling pathway and various cancer‑associated pathways. Silencing TAK1 may decrease cellular response to chemical stimulus via downregulating CYP3A5, MAP3K7, GSTA1, ALDH1A1, ARRB1 and ITPR1; increase cancer cell development via upregulating EGFR, EGR1 and PTHLH; and regulate cancer metastasis through EGFR, ERBB2, GRB2 and PIK3R1.
View Figures
View References

Related Articles

Journal Cover

May-2017
Volume 13 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen J, Zhang N, Wen J and Zhang Z: Silencing TAK1 alters gene expression signatures in bladder cancer cells. Oncol Lett 13: 2975-2981, 2017
APA
Chen, J., Zhang, N., Wen, J., & Zhang, Z. (2017). Silencing TAK1 alters gene expression signatures in bladder cancer cells. Oncology Letters, 13, 2975-2981. https://doi.org/10.3892/ol.2017.5819
MLA
Chen, J., Zhang, N., Wen, J., Zhang, Z."Silencing TAK1 alters gene expression signatures in bladder cancer cells". Oncology Letters 13.5 (2017): 2975-2981.
Chicago
Chen, J., Zhang, N., Wen, J., Zhang, Z."Silencing TAK1 alters gene expression signatures in bladder cancer cells". Oncology Letters 13, no. 5 (2017): 2975-2981. https://doi.org/10.3892/ol.2017.5819